Ru(II)-diimine labeled P450 mutants for the selective hydroxylation of substrate
Ru(II)-二亚胺标记的 P450 突变体用于底物的选择性羟基化
基本信息
- 批准号:8017192
- 负责人:
- 金额:$ 10.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-03-01 至 2015-02-28
- 项目状态:已结题
- 来源:
- 关键词:AccountingAcetaminophenActive SitesAdrenergic beta-AntagonistsAnabolismBindingBiodegradationCamphorCamphor 5-MonooxygenaseCarbonCarrier ProteinsComplexCoughingCysteineCytochrome P450DependenceDextromethorphanElectron TransportElectronsEnzymesGas ChromatographyGenerationsGoalsHemeHeme IronHumanHydrogen BondingHydroxylationIronLabelLeadLibrariesLifeLightMedicineMetabolismMixed Function OxygenasesModelingModificationMolecularOrganismOxidoreductaseOxygenPathway interactionsPharmaceutical PreparationsPhotosensitizing AgentsPlayPositioning AttributeProcessPropertyPropranololProteinsProviderPublishingReactionReactive Oxygen SpeciesRelative (related person)ResearchRestRoleRouteSite-Directed MutagenesisSourceSystemTerpenesVisible RadiationWatercofactorcytochrome P-450 CYP119 (Sulfolobus solfataricus)drug developmentdrug metabolismenzyme activityimprovedinnovationirradiationleukotoxinlimonenelong chain fatty acidmutantnovelnovel strategiesoxidationplanetary Atmospherescale upthermophilic organism
项目摘要
DESCRIPTION (provided by applicant): Cytochromes P450 are a superfamily of heme-thiolate monooxygenases, found in almost all living organisms, that play an important role in the biosynthesis and biodegradation of endogenous compounds. In humans, P450s are the major enzymes involved in drug metabolism and bioactivation, accounting for 75% of the total metabolism. The classical P450 reaction is the introduction of an oxygen atom, derived from molecular oxygen, into a substrate unactivated carbon center. The mechanism involves the reductive scission of the O-O bond at the iron center, leading to the formation of a highly oxidative heme radical ferryl species, namely Compound I. Most P450 monooxygenases are characterized by low activity, limited stability, need of an expensive cofactor (NAD(P)H) to reduce the heme iron and general dependence on auxiliary electron carrier proteins called reductases. We propose to develop a novel P450 system that will utilize light and water as the only source of oxygen atom to perform, under inert atmosphere, the selective hydroxylation of various substrate C-H bonds. This system will be used as a human P450 model to facilitate the identification of toxic metabolites early in the drug development process and to enable the diversification of lead compounds through the generation of a broad range of hydroxylated derivatives. The innovative part of this proposal is to replace the reductase by a photosensitizer Ru(II) diimine complex covalently attached to the heme domain. The reactive Compound I will then be generated, under inert atmosphere, via a photo-oxidative route directly from the water bound to the Fe(III) in the resting state of the enzyme rather than through the current reductive mechanism. This approach will enable the control of the electron flow between the photosensitizer and the heme domain while avoiding the rapid deactivation of the protein due to reactive oxygen species. The proposed system will result in enhanced activity of the enzymes towards the selective hydroxylation of substrate C-H bonds.
PUBLIC HEALTH RELEVANCE: This proposal aims at developing a novel biocatalyst to selectively insert an oxygen atom into a substrate C-H bond using visible light and water, under inert atmosphere. This system will be used as an innovative model of human P450 enzymes, which are responsible for the bioactivation and biodegradation of 75% of all drugs.
描述(由申请人提供):细胞色素P450是血红素硫醇单加氧酶的超家族,几乎存在于所有生物体中,在内源性化合物的生物合成和生物降解中发挥重要作用。在人体中,P450是参与药物代谢和生物活化的主要酶,占总代谢的75%。经典的 P450 反应是将分子氧衍生的氧原子引入底物未活性碳中心。其机制涉及铁中心 O-O 键的还原性断裂,导致形成高度氧化的血红素自由基,即化合物 I。大多数 P450 单加氧酶的特点是活性低、稳定性有限、需要昂贵的辅因子( NAD(P)H) 来减少血红素铁,并且一般依赖于称为还原酶的辅助电子载体蛋白。我们建议开发一种新型 P450 系统,该系统将利用光和水作为氧原子的唯一来源,在惰性气氛下进行各种底物 C-H 键的选择性羟基化。该系统将用作人类 P450 模型,以促进在药物开发过程的早期识别有毒代谢物,并通过生成广泛的羟基化衍生物来实现先导化合物的多样化。该提案的创新部分是用共价连接到血红素结构域的光敏剂Ru(II)二亚胺复合物代替还原酶。然后,在惰性气氛下,通过光氧化途径直接从与酶静止状态下的 Fe(III) 结合的水生成反应性化合物 I,而不是通过当前的还原机制。这种方法将能够控制光敏剂和血红素结构域之间的电子流,同时避免活性氧导致的蛋白质快速失活。所提出的系统将导致酶对底物 C-H 键选择性羟基化的活性增强。
公共健康相关性:该提案旨在开发一种新型生物催化剂,在惰性气氛下使用可见光和水选择性地将氧原子插入底物 C-H 键中。该系统将用作人类 P450 酶的创新模型,该酶负责 75% 的药物的生物活化和生物降解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lionel E. Cheruzel其他文献
シトクロムP450の補酵素依存脱却を目指したデコイ-光駆動水酸化反応系の開発
开发诱饵光驱动的羟基化反应系统,旨在消除细胞色素 P450 的辅酶依赖性
- DOI:
- 发表时间:
2021 - 期刊:
- 影响因子:0
- 作者:
大河内富夢;有安真也;愛場雄一郎;Lionel E. Cheruzel;荘司長三 - 通讯作者:
荘司長三
Lionel E. Cheruzel的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lionel E. Cheruzel', 18)}}的其他基金
Novel Strategies in Light-driven P450 Enzymes
光驱动 P450 酶的新策略
- 批准号:
10410303 - 财政年份:2022
- 资助金额:
$ 10.76万 - 项目类别:
Ru(II)-diimine labeled P450 mutants for the selective hydroxylation of substrate
Ru(II)-二亚胺标记的 P450 突变体用于底物的选择性羟基化
- 批准号:
8854787 - 财政年份:2011
- 资助金额:
$ 10.76万 - 项目类别:
Ru(II)-diimine labeled P450 mutants for the selective hydroxylation of substrate
Ru(II)-二亚胺标记的 P450 突变体用于底物的选择性羟基化
- 批准号:
8625311 - 财政年份:2011
- 资助金额:
$ 10.76万 - 项目类别:
Ru(II)-diimine labeled P450 mutants for the selective hydroxylation of substrate
Ru(II)-二亚胺标记的 P450 突变体用于底物的选择性羟基化
- 批准号:
8432445 - 财政年份:2011
- 资助金额:
$ 10.76万 - 项目类别:
Ru(II)-diimine labeled P450 mutants for the selective hydroxylation of substrate
Ru(II)-二亚胺标记的 P450 突变体用于底物的选择性羟基化
- 批准号:
8227958 - 财政年份:2011
- 资助金额:
$ 10.76万 - 项目类别:
相似国自然基金
CHAC1通过调控蛋白谷胱甘肽化修饰促进对乙酰氨基酚诱导急性药物性肝损伤的作用和机制研究
- 批准号:82370597
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
金银花中绿原酸类化合物通过激活Keap1/Nrf2-PPARα通路促进对乙酰氨基酚肝损伤后肝脏再生修复的研究
- 批准号:82304845
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于超小MOF-818构筑的纳米酶复合物催化前药对乙酰氨基酚的氧化及其抗肿瘤机制
- 批准号:32371463
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
IER2通过Hippo信号通路保护对乙酰氨基酚诱导的肝损伤
- 批准号:82373967
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
ENDOG促进对乙酰氨基酚引起肝损伤的作用及机制研究
- 批准号:82370596
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
Novel proteolytic mechanisms driving pathologic hepatic congestion in drug-induced hepatotoxicity
药物引起的肝毒性中驱动病理性肝充血的新蛋白水解机制
- 批准号:
10638320 - 财政年份:2023
- 资助金额:
$ 10.76万 - 项目类别:
Hepatocyte-targeted somatic-cell genetic complementation in mice
小鼠肝细胞靶向体细胞遗传互补
- 批准号:
10017365 - 财政年份:2019
- 资助金额:
$ 10.76万 - 项目类别:
Ru(II)-diimine labeled P450 mutants for the selective hydroxylation of substrate
Ru(II)-二亚胺标记的 P450 突变体用于底物的选择性羟基化
- 批准号:
8625311 - 财政年份:2011
- 资助金额:
$ 10.76万 - 项目类别:
Virtual High Throughput Screening: Specific Mechanism-based Inhibitors of CYP2E1
虚拟高通量筛选:基于特定机制的 CYP2E1 抑制剂
- 批准号:
8290572 - 财政年份:2011
- 资助金额:
$ 10.76万 - 项目类别:
Virtual High Throughput Screening: Specific Mechanism-based Inhibitors of CYP2E1
虚拟高通量筛选:基于特定机制的 CYP2E1 抑制剂
- 批准号:
8029735 - 财政年份:2011
- 资助金额:
$ 10.76万 - 项目类别: